Pathstone Holdings LLC Trims Holdings in Edwards Lifesciences Co. (NYSE:EW)

Pathstone Holdings LLC decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 29.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 89,558 shares of the medical research company's stock after selling 37,886 shares during the quarter. Pathstone Holdings LLC's holdings in Edwards Lifesciences were worth $5,910,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. LRI Investments LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $67,000. Lazard Asset Management LLC grew its position in shares of Edwards Lifesciences by 89.6% during the 1st quarter. Lazard Asset Management LLC now owns 93,629 shares of the medical research company's stock worth $8,946,000 after buying an additional 44,257 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Edwards Lifesciences by 57.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company's stock valued at $622,695,000 after acquiring an additional 2,390,137 shares during the last quarter. Bellevue Group AG raised its position in shares of Edwards Lifesciences by 8.3% in the 1st quarter. Bellevue Group AG now owns 1,103,136 shares of the medical research company's stock valued at $105,416,000 after acquiring an additional 84,138 shares during the period. Finally, Kennedy Capital Management LLC bought a new position in Edwards Lifesciences during the 1st quarter worth approximately $2,440,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on EW shares. Royal Bank of Canada dropped their price objective on Edwards Lifesciences from $85.00 to $75.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. Daiwa America cut Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 30th. Citigroup lowered their target price on Edwards Lifesciences from $83.00 to $77.00 and set a "buy" rating for the company in a research note on Tuesday, October 1st. Morgan Stanley reaffirmed an "equal weight" rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. Finally, Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a report on Monday, October 28th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Hold" and an average price target of $75.67.

Edwards Lifesciences Trading Up 0.1 %

NYSE EW traded up $0.10 during trading hours on Friday, hitting $70.48. 2,711,639 shares of the company's stock were exchanged, compared to its average volume of 5,390,755. The firm has a market cap of $41.57 billion, a price-to-earnings ratio of 10.17, a PEG ratio of 3.96 and a beta of 1.12. The stock has a 50-day simple moving average of $67.70 and a 200 day simple moving average of $75.73. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the firm posted $0.59 EPS. The company's quarterly revenue was up 8.9% on a year-over-year basis. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the business's stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,262,521.36. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,000 shares of company stock worth $2,657,000. Insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.